Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. April 2024 04:00 ET | Quelle: Molecure

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare...
30. März 2023 03:00 ET | Quelle: Molecure

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress Entering 2023 with strong momentum and a robust pipeline of proprietary, first-in-class compoundsFirst...
08. März 2023 09:00 ET | Quelle: Molecure

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer OATD-02 is an oral, potent and selective dual arginase...